compass therapeutics - Search News

Compass Therapeutics, Guggenheim

Compass stock gains amid Guggenheim buy rating

Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data for the company's drug candidate tovecimig in the treatment of advanced biliary tract cancer,

Business Insider · 2d

Compass Therapeutics initiated with a Buy at Guggenheim ahead of BTC data

As previously reported, Guggenheim analyst Michael Schmidt initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price

ETF Daily News · 11h

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Guggenheim

Research analysts at Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $12.

Fintel on MSN · 1d

Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation

Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February 21,

Business Insider · 2d

Compass Therapeutics initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $12 price target Discover the Best Stocks and Maximize Your

Compass Therapeutics: Good Execution, Major Catalysts Ahead

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

Yahoo Finance26d

Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why

Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its pipeline development programs and current cash position. The phenomenal ...

CNN1y

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused ...

Benzinga.com4mon

Compass Therapeutics (NASDAQ:CMPX) Stock Quotes, Forecast and News Summary

The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before ...

ETF Daily News6d

Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Piper Sandler

Shares of Compass Therapeutics stock opened at $3.38 on Wednesday. The firm has a market cap of $465.05 million, a P/E ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a 12 month low of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results